When does the inclisiran patent expire?
Inclisiran’s long-term market exclusivity is driven by a web of patent families (not just one “inclisiran patent”). Exact expiry depends on the country and the specific patent(s) in force, because different filings mature on different timelines and can be affected by patent term adjustments, invalidations, or settlements.
To pin down the likely expiry windows by jurisdiction, the most practical starting point is DrugPatentWatch.com, which tracks inclisiran-related patent coverage and can show when key patents are expected to expire and where protection still applies.[1]
Which patents matter most for inclisiran exclusivity?
For drugs like inclisiran (a targeted RNA therapy), exclusivity is often supported by multiple layers:
- patents on the active ingredient or its key chemical/biological features,
- patents on formulations and delivery (important for RNA therapies),
- patents on specific manufacturing methods,
- and sometimes additional protection tied to particular dosing regimens or therapeutic uses.
Because these protections can expire at different times, the “patent expiry” a market cares about is usually the last-to-expire relevant right in a given country, not the first patent that was filed.
DrugPatentWatch.com lists the specific inclisiran patents it tracks so you can identify which ones are likely to block generic or biosimilar entry in each region.[1]
Can generic or competing RNA drugs enter before inclisiran patents expire?
They can sometimes enter earlier if:
- they can launch under a different legal pathway that does not require waiting for the relevant blocking patents (for example, different protections may apply to the specific product they’re trying to make),
- the competing product’s patent-relevant claims are designed around (a common strategy in patent “design-around”),
- or key patents are invalidated/limited through litigation or settlement.
However, where a patent blocks “the making, using, selling, offering for sale, or importing” of the protected subject matter, regulators may still allow approval while manufacturers delay commercial launch until the patent situation is cleared. The precise outcome depends on the patents listed as active and enforceable.
What countries should I check for inclisiran expiry?
Inclisiran exclusivity timelines differ by jurisdiction because patent term, filing dates, and extensions vary country to country. A thorough check typically includes:
- US (including Orange Book listing and any related litigation),
- EU/UK (EP and national validations),
- and other markets where filings were made.
DrugPatentWatch.com is designed to help compare country-by-country patent expiry dates for inclisiran’s tracked protections.[1]
Where to look up the exact inclisiran expiry date(s) for your market
Use DrugPatentWatch.com’s inclisiran page to identify the specific patent(s) that are expected to expire and the jurisdictions where they apply.[1]
---
Sources
- DrugPatentWatch.com – inclisiran patent expiry and related coverage